Events - Spark Newswire

2 minute read

2 Cell Tower REITs With Above-Average Yields: A Great Buy During Coveted Fed Pivot?

December 13, 12:50 PM

SP Global data shows that, over a three-year period, cell tower real estate investment trusts (REITs) had the highest potential returns out of any other REIT sector of nearly 30%.

CCI

1 minute read

BeyondSpring Presents Data With Plinabulin For The Prevention Of Docetaxel-Induced Neutropenia In Patients With Non-Small Cell Lung Cancer And Breast Cancer At Three Medical Conferences

By Benzinga Newsdesk

December 13, 9:08 AM

Additional analyses of non-small cell lung cancer (NSCLC) studies support the efficacy of plinabulin monotherapy in reducing the mean duration of severe neutropenia (DSN) for patients receiving docetaxel In an

BYSI

4 minute read

Galapagos And CellPoint Presented Initial Data At ASH 2022 For GLPG5101, A CD19 CAR-T Candidate Manufactured At Point-Of-Care

By Benzinga Newsdesk

December 13, 3:04 AM

6 out of 7 eligible patients with relapsed/refractory Non-Hodgkin Lymphoma (rrNHL) responded to treatment (ORR of 86%) and all responding patients achieved complete response (CR) No grade 3 or higher cytokine

GLPG

2 minute read

Reported Late Monday, NGM Bio Gives Presentation Featuring Preclinical Characterization Of NGM936 At 2022 ASH Annual Meeting

By Benzinga Newsdesk

December 13, 1:27 AM

--NGM936, a ILT3 x CD3 bispecific T cell engager product candidate, potently induced T cell dependent cytotoxicity (TDCC) against ILT3+ AML cells while inducing minimal cytokine release in preclinical in vivo and in

NGM

1 minute read

Pfizer Sees Potential Revenues Of More Than $2B From Respiratory Syncytial Virus Vaccine Candidate, Sees Peak Sales In 2027; Presentation To Begin At 1:00 p.m ET

By Benzinga Newsdesk

December 12, 1:55 PM

https://investors.pfizer.com/Investors/Events--Presentations/event-details/2022/Pfizer-Near-Term-Launches--High-Value-Pipeline-Day/default.aspx Pfizer Near-Term Launches + High-Value Pipeline Day Start date:

PFE

2 minute read

This US Rep Bought 3 Vanguard ETFs Paying Monthly Dividends, Saw Gains In Recent Trades

By Robert Kuczmarski

December 12, 12:23 PM

Congressman Kurt Schrader of Oregon was last covered by Benzinga for his trades on Ameren Corporation (NYSE: AEE) and SLB (NYSE: SLB), which were made on Oct. 13 and Oct. 26, respectively.

AEE

5 minute read

Regeneron Pharmaceuticals, Linvoseltamab Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses In Patients With Heavily Pre-Treated Multiple Myeloma

By Benzinga Newsdesk

December 12, 11:12 AM

As presented at ASH, recommended 200 mg dose of linvoseltamab demonstrated a 64% response rate, with 45% of responders achieving a very good partial response or better; responses may further improve

REGN

1 minute read

Affimed Presents Updated Data For AFM28 Demonstrating Efficient Elimination Of Leukemic Stem And Progenitor Cells In Combination With Allogeneic NK Cells In Preclinical Models Of Acute Myeloid Leukemia And Myelodysplastic Syndrome At The ASH 2022 Meeti…

By Benzinga Newsdesk

December 12, 11:10 AM

AFM28 efficiently directs allogeneic NK cells to CD123-positive leukemic cells, including leukemic stem and progenitor cells, inducing their depletion in samples of patients with Acute Myeloid Leukemia (AML) and

AFMD

3 minute read

Xencor Presents Data From Phase 1 Study Of Plamotamab In Relapsed Or Refractory Non-Hodgkin Lymphoma At The American Society Of Hematology Annual Meeting

By Benzinga Newsdesk

December 12, 11:09 AM

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced additional clinical data from

XNCR

1 minute read

Nektar Announces Poster Presentations At The 64th American Society Of Hematology Annual Meeting

By Benzinga Newsdesk

December 12, 11:07 AM

-- Unveils Trial Design for Nektar Phase 2/3 Study Combining NKTR-255 with CAR-T Therapies -- -- Presents First Data for NKTR-255 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple

NKTR